Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/29361
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hablase, R | - |
dc.contributor.author | Kyrou, I | - |
dc.contributor.author | Randeva, H | - |
dc.contributor.author | Karteris, E | - |
dc.contributor.author | Chatterjee, J | - |
dc.date.accessioned | 2024-07-16T08:43:08Z | - |
dc.date.available | 2024-07-16T08:43:08Z | - |
dc.date.issued | 2024-06-06 | - |
dc.identifier | ORCiD: Ioannis Kyrou https://orcid.org/0000-0002-6997-3439 | - |
dc.identifier | ORCiD: https://orcid.org/0000-0003-3231-7267 | - |
dc.identifier | ORCiD: Jayanta Chatterjee https://orcid.org/0000-0002-1770-4835 | - |
dc.identifier | 2160 | - |
dc.identifier.citation | Hablase, R. et al. (2024) 'The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review', Cancers, 16 (11), 2160, pp. 1 - 28. doi: 10.3390/cancers16112160. | en_US |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/29361 | - |
dc.description | Data Availability Statement: No extra data is generated in this review article. | en_US |
dc.description.abstract | Ovarian cancer is an umbrella term covering a number of distinct subtypes. Endometrioid and clear-cell ovarian carcinoma are endometriosis-associated ovarian cancers (EAOCs) frequently arising from ectopic endometrium in the ovary. The mechanistic target of rapamycin (mTOR) is a crucial regulator of cellular homeostasis and is dysregulated in both endometriosis and endometriosis-associated ovarian cancer, potentially favouring carcinogenesis across a spectrum from benign disease with cancer-like characteristics, through an atypical phase, to frank malignancy. In this review, we focus on mTOR dysregulation in endometriosis and EAOCs, investigating cancer driver gene mutations and their potential interaction with the mTOR pathway. Additionally, we explore the complex pathogenesis of transformation, considering environmental, hormonal, and epigenetic factors. We then discuss postmenopausal endometriosis pathogenesis and propensity for malignant transformation. Finally, we summarize the current advancements in mTOR-targeted therapeutics for endometriosis and EAOCs. | en_US |
dc.description.sponsorship | This research received no external funding. | en_US |
dc.format.extent | 1 - 28 | - |
dc.format.medium | Electronic | - |
dc.language | English | - |
dc.language.iso | en_US | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Copyright © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject | ovarian cancer | en_US |
dc.subject | mTOR | en_US |
dc.subject | endometriosis | en_US |
dc.subject | endometrioid ovarian carcinoma | en_US |
dc.subject | clear-cell carcinoma | en_US |
dc.subject | mTOR inhibitors | en_US |
dc.title | The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review | en_US |
dc.type | Article | en_US |
dc.date.dateAccepted | 2024-06-01 | - |
dc.identifier.doi | https://doi.org/10.3390/cancers16112160 | - |
dc.relation.isPartOf | Cancers | - |
pubs.issue | 11 | - |
pubs.publication-status | Published | - |
pubs.volume | 16 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.rights.license | https://creativecommons.org/licenses/by/4.0/legalcode.en | - |
dc.rights.holder | The authors | - |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | 1.27 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License